Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

334 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-20

Study Completion Date

2020-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and 160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

NCT00133003

Coronary Disease Angina, Unstable

COMPLETED PHASE4

Phase III Acute Coronary Syndrome

NCT00831441

Acute Coronary Syndrome

TERMINATED PHASE3

Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)

NCT00390832

Myocardial Infarction Angioplasty, Transluminal, Percutaneous Coronary

COMPLETED PHASE3

Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions

NCT03022877

Myocardial Infarction Outcome

WITHDRAWN NA

PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy

NCT03392948

Acute Myocardial Infarction Unstable Angina Chronic Stable Angina

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Revacept is a protein that is made up of an Fc fragment ("fragment crystallisable") fused to the GPVI receptor (the endogenous platelet collagen receptor). Consequently, Revacept binds to its ligand (collagen) on atherosclerotic plaques preventing circulating thrombocytes from binding to collagen exposed by the injured plaque. All this is achieved without affecting systemic hemostasis.

Thus, blocking of GPVI-dependent pathways by interfering with vascular collagen sites is commonly seen as an attractive target for an anti-platelet therapy of atherosclerotic diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stable Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

with 2 doses (80 and 160 mg) of Revacept versus placebo

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Revacept 80 mg

single dose, intravenous

Group Type EXPERIMENTAL

Revacept 80 mg

Intervention Type DRUG

single dose, intravenous application of 80 mg Revacept

Revacept 160 mg

single dose, intravenous

Group Type EXPERIMENTAL

Revacept 160 mg

Intervention Type DRUG

single dose, intravenous application of 180 mg Revacept

Placebo

single dose, intravenous

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

single dose, intravenous application of Placebo solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Revacept 80 mg

single dose, intravenous application of 80 mg Revacept

Intervention Type DRUG

Revacept 160 mg

single dose, intravenous application of 180 mg Revacept

Intervention Type DRUG

Placebo

single dose, intravenous application of Placebo solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed written informed consent
* Men and women \>18 years of age
* Diagnosis: Clinically stable coronary artery disease
* Angiographic evidence of coronary artery disease
* Indication for PCI

Exclusion Criteria

* WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for up to 4 weeks after receiving investigational product.
* Women who are pregnant or breastfeeding or are planning pregnancy during course of trial
* Women with a positive pregnancy test on enrolment or prior to investigational product administration.
* Patients with elevated high sensitivity cardiac troponin T levels at screening
* Patients receiving antithrombotic therapy with Prasugrel or Ticagrelor within 7 days prior to randomisation
* History of hypersensitivity, contraindication or serious adverse reaction to any component of the study drug (GPVI-Fc, sucrose, mannitol), acetylsalicylic acid or clopidogrel
* History of bleeding diathesis or active bleeding within the last 30 days
* Recent intracerebral haemorrhage or trauma within the last 3 months
* Thrombocytopenia (platelet count \<30000/mm3) at screening
* Sustained hypertension (systolic BP \>179mmHg or diastolic BP \>109mmHg) at screening
* Renal failure (estimated glomerular filtration rate \< 30ml/min and/or dialysis)
* Severe systemic disease, such as known malignancies or other comorbid conditions with life expectancy less than one year that may result in protocol non-compliance
* Unable to provide informed consent (e.g. severe dementia, or psychosis)
* Current severe liver dysfunction (transaminase level \>5-fold the upper normal range limit)
* Patients with an indication for anticoagulant therapy
* Participation in any other clinical interventional trial (drug/device) within less than 30 days prior to screening
* Any other contraindication to perform PCI
* Any planned additional PCI or surgery within 30 days after randomization
* Suspected poor capability to follow instructions and cooperate
* Prisoners or subjects who are involuntarily incarcerated
* Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness (e.g. infectious disease)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No